Comorbid conditions in patients with chronic heart failure (according to the registry of chronic heart failure in the Tyumen region)

Cover Page

Cite item

Full Text

Abstract

Background. Comorbidity in patients with chronic heart failure (CHF) makes a major impact to the course of both the underlying and concomitant diseases, significantly worsens the prognosis and increases mortality from cardiovascular diseases. Improving specialized treatment within the framework of a three-tier model of providing medical care to patients with CHF is a healthcare priority.

Aim. Analysis of the frequency of comorbid conditions in patients with CHF included in the CHF registry in the Tyumen region.

Materials and methods. The study was conducted using the CHF register method, which has been operating in the Tyumen region since January 2020. Medical data from outpatient cards and discharge reports were entered by doctors from 9 polyclinics with an attached population, 1 consultative polyclinic, hospitals, on the basis of which there are outpatient CHF rooms in the structure of polyclinics in the city of Tobolsk, Zavodoukovsk, with. Nizhnyaya Tavda, Yalutorovsk, Tyumen Region, Ural Federal District. The study included medical data of 5741 patients with CHF I–IV functional classes (FC). Gender, clinical-instrumental and laboratory data, non-cardiac and cardiac diseases according to the International Classification of Diseases of the 10th revision were entered into a single map of the CHF registry.

Results. In the study sample of patients with CHF, whose average age was 70.0±9.7 years, 2331 (40.6%) were men and 3410 (59.4%) were women. The most common cardiovascular diseases were: coronary artery disease – 55.4%, HD – 22.5% and HRT – 13.5% of cases. Among concomitant diseases of non-cardiac reasons, diabetes mellitus was most often noted – in 31.5% of cases, chronic kidney disease – in 31.1% and chronic obstructive pulmonary disease – in 10% of cases. Concomitant diseases were more common in patients with CHF of functional classes III–IV.

Conclusion. Maintaining a register of CHF and analyzing register data makes it possible to assess the required volume of medical care, plan the necessary time, material, economic and organizational resources and take into account possible difficulties in diagnosis, treatment and outpatient monitoring.

About the authors

Anna A. Airapetian

Chazov National Medical Research Center of Cardiology

Author for correspondence.
Email: A.A.Airapetian@yandex.ru
ORCID iD: 0000-0002-7064-5328

research laboratory assistant

Russian Federation, Moscow

Natalia V. Lazareva

Chazov National Medical Research Center of Cardiology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-3253-0669

Cand. Sci. (Med.)

Russian Federation, Moscow

Oleg M. Reitblat

Tyumen State Medical University; Regional Clinical Hospital No1; Ministry of Health of the Russian Federation

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-9407-5497

Cand. Sci. (Med.)

Russian Federation, Tyumen; Tyumen; Moscow

Evgeny M. Mezhonov

Tyumen State Medical University; Regional Clinical Hospital No1

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-6086-4578

D. Sci. (Med.)

Russian Federation, Tyumen; Tyumen

Evgeny V. Evgeny

Chazov National Medical Research Center of Cardiology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-8395-937X

Cand. Sci. (Med.)

Russian Federation, Moscow

Yulia Sh. Prints

Regional Clinical Hospital No1; Department of Health of the Tyumen Region

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-8331-6307

Department of Cardiology Head

Russian Federation, Tyumen; Tyumen

Igor V. Zhirov

Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4066-2661

D. Sci. (Med.)

Russian Federation, Moscow; Moscow

Sergey N. Tereshchenko

Chazov National Medical Research Center of Cardiology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-9234-6129

D. Sci. (Med.)

Russian Federation, Moscow

Sergey A. Boytsov

Chazov National Medical Research Center of Cardiology; Ministry of Health of the Russian Federation

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-6998-8406

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Mocow; Moscow

References

  1. WHO Global Action Plan for the Prevention and Control of Non-communicable Diseases 2013–2020 (resolution WHA66.10, 27 May 2013). Available at: https://www.who.int/publications/i/item/9789241506236. Accessed: 19.08.2019.
  2. Wong CY, Chaudhry SL, et al. Treads in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136-43. doi: 10.1016/j.amjmed.2010.08.017
  3. Чумбуридзе В., Кикалишвили Т. Коморбидные состояния при хронической сердечной недостаточности: как оптимизировать лечение? Неотложная кардиология и кардиоваскулярные риски. 2018;2(1):286-90. [Chumburidze V, Kikalishvili T. Komorbidnye sostoyaniya pri chronicheskoy serdechnoy nedostatochnosti: kak optimizirovat’ lechenie [Comorbidities in Heart Failure: How to Optimize the Treatment?]. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks]. 2018;2(1):286-90 (in Russian)]. EDN:XQZNRB
  4. van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103-11. doi: 10.1002/ejhf.30
  5. Iyngkaran P, Majoni W, Cass A, et al. Northern Territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base. Heart Lung Circ. 2015;24(6):536-43. doi: 10.1016/j.hlc.2014.12.007
  6. Lawson CA, Zaccardi F, Squire I, et al. Risk factors for heart failure. 20-year population-based trends by sex, socioeconomic status, and ethnicity. Circ Heart Fail. 2020;13(2):e006472. doi: 10.1161/CIRCHEARTFAILURE.119.006472
  7. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083 [2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (in Russian)]. doi: 10.15829/1560-4071-2020-4083
  8. Артериальная гипертензия у взрослых. Клинические рекомендации (проект) 2022. Российское кардиологическое общество. Российское научное медицинское общество терапевтов. Режим доступа: https://scardio.ru/content/Guidelines/project/KR_AGpdf. Ссылка активна на 01.03.2023 [Arterial'naia gipertenziia u vzroslykh. Klinicheskie rekomendatsii (proekt) 2022. Rossiiskoe kardiologicheskoe obshchestvo. Rossiiskoe nauchnoe meditsinskoe obshchestvo terapevtov. Available at: https://scardio.ru/content/Guidelines/project/KR_AGpdf. Accessed: 01.03.2023 (in Russian)].
  9. Бойцов С.А. Хроническая сердечная недостаточность: эволюция этиологии, распространенности и смертности за последние 20 лет. Терапевтический архив. 2022;94(1):5-8 [Boytsov SA. Chronic heart failure: Evolution of etiology, prevalence and mortality over the past 20 years. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):5-8 (in Russian)]. doi: 10.26442/00403660.2022.01.201317
  10. Spinar J, Parenica J, Vitovec J, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care. 2011;15(6):R291. doi: 10.1186/cc10584
  11. Бойцов С.А., Бланкова З.Н., Свирида О.Н., и др. Первые результаты мероприятий по совершенствованию оказания медицинской помощи пациентам с хронической сердечной недостаточностью в разных регионах Российской Федерации. Часть I. Организация помощи при хронической сердечной недостаточности и распространенность заболевания с низкой и сохраненной фракцией выброса левого желудочка. Кардиологический вестник. 2023;18(2):19-28 [Boytsov SA, Blankova ZN, Svirida ON, et al. The first results of advanced medical care for chronic heart failure in different regions of the Russian Federation. Part I. Organization of care for chronic heart failure and prevalence of disease with reduced and preserved left ventricular ejection fraction. Russian Cardiology Bulletin. 2023;18(2):19-28 (in Russian)]. doi: 10.17116/Cardiobulletin20231802119
  12. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-Card). J Cardiol. 2013;62(2):95-101. doi: 10.1016/j.jjcc.2013.03.009
  13. Sato N, Kajimoto K, Asai K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159(6):949-55.e1. doi: 10.1016/j.ahj.2010.03.019
  14. Лазарева Н.В., Ощепкова Е.В., Терещенко С.Н. Коморбидность у больных с хронической сердечной недостаточностью (по данным регистра ХСН). Кардиологический вестник. 2016;(4):25-9 [Lazareva NV, Oshchepkova EV, Tereshchenko SN. Komorbidnost' u bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu (po dannym registra KhSN). Kardiologicheskii vestnik. 2016;(4):25-9 (in Russian)].
  15. Abraham WT, Fonarow GC, Albert NM, et al. Predictor of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52(5):347-56. doi: 10.1016/j.jacc.2008.04.028
  16. Jonsson A, Edner M, Alehagen U, Dahlström U. Heart failure register: A valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12(1):25-31. doi: 10.1093/eurjhf/hfp175
  17. Ruiz-Laiglesia FJ, Sánchez-Marteles M, Pérez-Calvo JI, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107(12):989-94. doi: 10.1093/qjmed/hcu127
  18. Поляков Д.С., Фомин И.В., Беленков Ю.Н. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. Кардиология. 2021;61(4):4-14 [Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. doi: 10.18087/cardio.2021.4.n1628
  19. García-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: A cross sectional study. BMC Fam Pract. 2013;14:11. doi: 10.1186/1471-2296-14-11
  20. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17(1):54-75. doi: 10.1016/j.cardfail.2010.08.010
  21. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J. 2014;35(7):455-69. doi: 10.1093/eurheartj/eht386
  22. Silverberg DS, Wexler D, Blum M, et al. The interaction between heart failure, renal failure and anemia – the cardio-renal anemia syndrome. Blood Purif. 2004;22(3):277-84. doi: 10.1159/000078698
  23. Ding N, Shah A, Blaha M, et al. Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction. J Am Coll Cardiol. 2022;79(23):2298-305. doi: 10.1016/j.jacc.2022.03.377
  24. Lavie CJ, Arena R, Alpert MA, et al. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol. 2018;15(1):45-56. doi: 10.1038/nrcardio.2017.108
  25. Сафиуллина А.А., Ускач Т.М., Сайпудинова К.М., и др. Сердечная недостаточность и ожирение. Терапевтический архив. 2022;94(9):1115-21 [Safiullina AA, Uskach TM, Saipudinova KM, et al. Heart failure and obesity. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(9):1115-21 (in Russian)]. doi: 10.26442/00403660.2022.09.201837
  26. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305-13. doi: 10.1056/NEJMoa020245
  27. Ткаченко Е.И., Боровкова Н.Ю., Буянова М.В. Анемия при хронической сердечной недостаточности: взгляд на патогенез и пути коррекции. Доктор.Ру. 2019;2(157):31-6 [Tkachenko EI, Borovkova NYu, Buyanova MV. Anemia in patients with chronic heart failure: A view of pathogenesis and treatment options. Doctor.Ru. 2019;2(157):31-6 (in Russian)]. doi: 10.31550/1727-2378-2019-157-2-31-36
  28. Соломахина Н.И., Находнова Е.С., Ершов В.И. Анемия при хронической сердечной недостаточности: роль гепсидина как универсального регулятора метаболизма железа. Сердечная недостаточность. 2014;85(4):254-60 [Solomakhina NI, Nakhodnova ES, Ershov VI. Anemiia pri khronicheskoi serdechnoi nedostatochnosti: rol' gepsidina kak universal'nogo reguliatora metabolizma zheleza. Serdechnaia nedostatochnost'. 2014;85(4):254-60 (in Russian)].
  29. Шаварова Е.К., Бабаева Л.А., Падарьян С.С., и др. Хроническая сердечная недостаточность: рекомендации и реальная клиническая практика. Рациональная фармакотерапия в кардиологии. 2016;12(6):631-7 [Shavarova EK, Babaeva LA, Padaryan SS, et al. Chronic heart failure: Clinical guidelines and real clinical practice. Rational Pharmacotherapy in Cardiology. 2016;12(6):631-7 (in Russian)]. doi: 10.20996/1819-6446-2016-12-6-631-637
  30. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation. 2018;138(1):80-98. doi: 10.1161/CIRCULATIONAHA.118.030099
  31. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohortof 12 065 patients with newonset heart failure. Circulation. 2003;107(2):223-5. doi: 10.1161/01.cir.0000052622.51963.fc
  32. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832-45. doi: 10.7326/0003-4819-148-11-200806030-00225
  33. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 2011;97(3):852-61. doi: 10.1210/jc.2011-1978
  34. Kannel WB. Epidemiology and prevention of cardiac failure: framingham study insights. Eur Heart J. 1987;8(SUPPL. F):23-8. doi: 10.1093/eurheartj/8.suppl_f.23
  35. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040-9. doi: 10.1161/CIRCULATIONAHA.112.096024
  36. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799-809. doi: 10.1001/archinternmed.2012.402
  37. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365-74. doi: 10.1001/jama.2010.1361
  38. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040-9. doi: 10.1161/CIRCULATIONAHA.112.096024
  39. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799-809. doi: 10.1001/archinternmed.2012.402

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies